When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Open accessThe DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Abstract
While Alzheimer’s disease (AD) classical diagnostic criteria rely on clinical data from a stablished symptomatic disease, newer criteria aim to identify the disease in its earlier stages. For that, they incorporated the use of AD’s specific biomarkers to reach a diagnosis, including the identification of Aβ and tau depositions, glucose hypometabolism, and cerebral atrophy. These biomarkers created a new concept of the disease, in which AD’s main pathological processes have already taken place decades before we can clinically diagnose the first symptoms. Therefore, AD is now considered a dynamic disease with a gradual progression, and dementia is its final stage. With that in mind, new models were proposed, considering the orderly increment of biomarkers and the disease as a continuum, or the variable time needed for the disease’s progression. In 2011, the National Institute on Aging and the Alzheimer’s Association (NIA-AA) created separate diagnostic recommendations for each stage of the disease continuum—preclinical, mild cognitive impairment, and dementia. However, new scientific advances have led them to create a unifying research framework in 2018 that, although not intended for clinical use as of yet, is a step toward shifting the focus from the clinical symptoms to the biological alterations and toward changing the future diagnostic and treatment possibilities. This review aims to discuss the role of biomarkers in the onset of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nonetheless, pathological changes in the brain begin during the preclinical stage, decades before clinical symptoms.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 10×
“In early AD, the first detectable signs that can be observed in a structural MRI are atrophy in the middle temporal lobe (affecting specially the hippocampus), and a decrease in the thickness of the cerebral cortex in regions that are vulnerable to AD [73–81].”
BackgroundInfluentialImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · cited 10×
“Indeed, it is included in both the Dubois [8] and the NIA-AA [16] diagnostic criteria and its specificity and sensitivity as an AD marker is greater than 85% [60].”
BackgroundMethodInfluentialInterplay between Cortical Spreading Depolarization and Seizures
Kramer, D. R., Fujii, T., Ohiorhenuan, I., & Liu, C. Y. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000452841 · Cited by 3,696
An Energy Budget for Signaling in the Grey Matter of the Brain
Attwell, D., & Laughlin, S. B. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200110000-00001 · Cited by 3,543 · cited 1×
“In addition, it correlates with decreased levels of synaptophysin found post-mortem that indicate a loss of synaptic activity [58,59].”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“4,20,21 Therefore, it ’ s crucial to concentrate on the preclinical and MCI stages, where early intervention and management of modi fi able risk factors could potentially lower the risk of onset or delay the progression of disease.”
BackgroundThe complexity of Alzheimer’s disease: an evolving puzzle
Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 309
Pontecorvo, M. J., Lu, M., Burnham, S. C., Schade, A. E., Dage, J. L., Shcherbinin, S., Collins, E. C., Sims, J. R., & Mintun, M. A. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3392 · Cited by 261
Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
McGrowder, D. A., Miller, F., Vaz, K., Nwokocha, C., Wilson-Clarke, C., Anderson-Cross, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 167
Cognitive Decline in Early and Premature Menopause
Sochocka, M., Karska, J., Pszczołowska, M., Ochnik, M., Fułek, M., Fułek, K., Kurpas, D., Chojdak-Łukasiewicz, J., Rosner‐Tenerowicz, A., & Leszek, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076566 · Cited by 164
“It should be noted that the underlying pathology of dementia can begin even 20 years prior to the onset of clinical symptoms of the disease [74].”
BackgroundBiomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
DementiaBank: Theoretical Rationale, Protocol, and Illustrative Analyses
Lanzi, A. M., Saylor, A. K., Fromm, D., Liu, H., MacWhinney, B., & Cohen, M. L. (2023) · American Journal of Speech-Language Pathology · doi:10.1044/2022_ajslp-22-00281 · Cited by 106
“Indeed, the neuropathological process of AD begins years to decades before the onset of obvious clinical symptoms (Golde et al., 2011; Jack et al., 2009; Lloret et al., 2019; Snowdon et al., 1996).”
BackgroundThe Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?
Kurkinen, M. T., Fułek, M., Fułek, K., Beszłej, J. A., Kurpas, D., & Leszek, J. (2023) · Biomolecules · doi:10.3390/biom13030453 · Cited by 114
Valverde-Salazar, V., Ruiz-Gabarre, D., & García‐Escudero, V. (2023) · Antioxidants · doi:10.3390/antiox12071460 · Cited by 85
“Current frameworks establish that, temporally, pathophysiological evidence of AD can be found 20–30 years before the beginning of symptoms that constitute the clinical phase of the disease, with molecular, cellular, biochemical, and functional alterations that have been linked to the development of symptoms later in l…”
BackgroundDevelopments in scalable strategies for detecting early markers of cognitive decline
Whelan, R., Barbey, F. M., Cominetti, M. R., Gillan, C. M., & Rosická, A. M. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02237-w · Cited by 77
“On the other hand, Aβ42 has a higher propensity to form toxic oligomers, which are present in CSF decades before AD onset [24, 25].”
BackgroundAbdullah, S. A., Najm, L., Ladouceur, L., Ebrahimi, F., Shakeri, A., Al‐Jabouri, N., Didar, T. F., & Dellinger, K. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202302673 · Cited by 68
Malkov, A., Popova, I., Ivanov, A., Jang, S.-S., Yoon, S. Y., Osypov, A., Huang, Y., Zilberter, Y., & Zilberter, M. (2021) · Communications Biology · doi:10.1038/s42003-021-02551-x · Cited by 59
A Critical Review of the Study of Neuroprotective Diets to Reduce Cognitive Decline
Duplantier, S. C., & Gardner, C. D. (2021) · Nutrients · doi:10.3390/nu13072264 · Cited by 55
“Early therapeutic action is needed to address biological processes that may already be compromised, and before AD progresses from a state of mild cognitive impairment (MCI) to cognitive failure [6].”
BackgroundMitochondrial dysfunction in Alzheimer’s disease - a proteomics perspective
Abyadeh, M., Gupta, V., Chitranshi, N., Gupta, V., Wu, Y., Saks, D., Wall, R. V., Fitzhenry, M. J., Basavarajappa, D. K., You, Y., et al. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1918550 · Cited by 52
Monllor, P., Cervera‐Ferri, A., Lloret, M.-Á., Esteve, D., Lopez, B., Leon, J.-L., & Lloret, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910889 · Cited by 55
Self-citationPuranik, N., & Song, M. (2024) · Molecules · doi:10.3390/molecules29235744 · Cited by 55
Protein clearance strategies for disease intervention
Hommen, F., Bilican, S., & Vílchez, D. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02431-y · Cited by 51
“Since AD begins to develop in patients decades before the first symptoms appear, it is important to determine an administration regimen for therapeutic compounds in AD (Beason-Held et al. 2013; Lloret et al. 2019).”
BackgroundUnraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., & Raheem, A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00845-5 · Cited by 49
“AD predominantly affects older individuals [10].”
Gut dysbiosis as a potential driver of Parkinson’s and Alzheimer’s disease pathogenesis
Pfaffinger, J. M., Hays, K. E., Seeley, J., Babu, P. R., & Ryznar, R. J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1600148 · Cited by 44
Progranulin in neurodegenerative dementia
Wang, X., Zeng, P. H., Fang, Y., Zhang, T., & Tian, Q. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15378 · Cited by 40
“In addition to NFTs, another major feature of AD pathology is the deposition of extracellular SPs composed of aggregated Aβ; Aβ is formed by the amyloidogenic cleavage of the amyloid precursor protein (APP) (Fagiani et al., 2019; Lloret et al., 2019; Wang et al., 2020).”
BackgroundSjöqvist, S., Otake, K., & Hirozane, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249425 · Cited by 37
“Cerebrospinal fluid (CSF) holds great promise as a source for CNS biomarkers, and its analysis is already used widely in clinical decision-making [2].”
BackgroundYan, Y., Aierken, A., Wang, C., Song, D. F., Ni, J., Wang, Z., Quan, Z., & Qing, H. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.009 · Cited by 33
Liang, Y., Xue, K., Shi, Y., Zhan, T., Lai, W., & Zhang, C. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c05164 · Cited by 32
Khan, A. F., & Iturria‐Medina, Y. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03073-w · Cited by 35
“The pathological processes underlying sporadic neurodegenerative disorders such as AD and PD also begin decades before their characteristic symptoms [45, 58, 83].”
BackgroundLloret, A., Esteve, D., Lloret, M.-Á., Monllor, P., López, B., Leon, J. L. A., & Cervera‐Ferri, A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.708061 · Cited by 31
Self-citationTeixeira, L. C. R., Luizon, M. R., & Gomes, K. B. (2025) · Receptors · doi:10.3390/receptors4010002 · Cited by 31
Wahlberg, K. E., Winblad, B. G., Cole, A., Herring, W. L., Ramsberg, J., Torontali, I., Visser, P. J., Wimo, A. B., Wollaert, L., & Jönsson, L. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13759 · Cited by 28
“These processes have therefore gained attention as promising targets for the development of early AD diagnostics [8] and disease-modifying therapies (DMTs) that can prevent or slow the progression of AD [9, 10].”
BackgroundAir pollution: a latent key driving force of dementia
Mohammadzadeh, M., Khoshakhlagh, A. H., & Grafman, J. H. (2024) · BMC Public Health · doi:10.1186/s12889-024-19918-4 · Cited by 26
“Among the most important diagnostic imaging tools for dementia are PET imaging with 2-deoxy-positron emission tomography (PiB-PET), 2 [18F] fluoro-D-glucose tracer (FDG-PET) and Structural and Functional Magnetic Resonance Imaging (MRI) [90].”
Lanzi, A. M., Saylor, A. K., & Cohen, M. L. (2022) · American Journal of Speech-Language Pathology · doi:10.1044/2022_ajslp-21-00266 · Cited by 30
Liu, X., Guo, L., Duan, B., Wu, J., & Wang, E. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.08.003 · Cited by 25
Effect of ivabradine on cognitive functions of rats with scopolamine-induced dementia
Assi, A.-A. A., Abdelnabi, S., Attaai, A., & Abd-ellatief, R. B. (2022) · Scientific Reports · doi:10.1038/s41598-022-20963-5 · Cited by 24
Yoong, S. Q., Lu, J., Xing, H., Gyanwali, B., Tan, Y., & Wu, X. V. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101491 · Cited by 24
Mapping cerebral atrophic trajectory from amnestic mild cognitive impairment to Alzheimer’s disease
Wei, X., Du, X., Xie, Y., Suo, X., He, X., Ding, H., Zhang, Y., Ji, Y., Chai, C., Liang, M., et al. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac137 · Cited by 23
LncRNA HOTAIR in exercise-induced neuro-protective function in Alzheimer’s disease
Lü, J., Liu, L., Chen, J., Zhi, J., Li, J., Li, L., & Jiang, Z. (2022) · Folia Neuropathologica · doi:10.5114/fn.2022.118961 · Cited by 23
“Specific biomarkers have their predominance in recognizing AD, since they may diagnose AD patients before clinical diagnose of primary symptoms [18].”
BackgroundPresent and Future of Blood-Based Biomarkers of Alzheimer’s Disease: Beyond the Classics
Grigoli, M. M., Pelegrini, L. N. D. C., Whelan, R., & Cominetti, M. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148812 · Cited by 22
Biomarkers and Cognition Study, Singapore (BIOCIS): Protocol, Study Design, and Preliminary Findings
Leow, Y. J., Wang, J. D. J., Vipin, A., Sandhu, G. K., Soo, S. A., Kumar, D., Mohammed, A. A., Zailan, F. Z., Lee, F. P. H. E., Ghildiyal, S., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.89 · Cited by 23
Chalkias, E., Topouzis, F., Tegos, T. J., & Tsolaki, M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201516 · Cited by 21
“Namely, these biomarkers include magnetic resonance imaging (MRI) findings of atrophy, predominantly of the hippocampus, amygdala, or entorhinal cortex, CSF protein biomarkers, PET findings, and specific gene mutations [7, 10].”
Update on Major Neurocognitive Disorders
Jones, K. C. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20210004 · Cited by 21
Wang, S., Kang, D. W., Um, Y. H., Kim, S., Lee, C. U., & Lim, H. K. (2023) · Biomolecules · doi:10.3390/biom13091336 · Cited by 19
“Clinico-pathophysiological changes associated with AD begin decades before clinical symptom onset [3].”
BackgroundPaolis, M. L. D., Loffredo, G., Krashia, P., Barbera, L. L., Nobili, A., Cauzzi, E., Babicola, L., Segni, M. D., Coccurello, R., Puglisi‐Allegra, S., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01736-4 · Cited by 19
“Nevertheless, pathological changes associated with AD begin in the brain during the preclinical stage, often decades before the appearance of clinical symptoms [2].”
Kapasouri, E. M., Ioannidis, D. C., Cameron, D., Vassiliou, V. S., & Hornberger, M. (2022) · Diagnostics · doi:10.3390/diagnostics12122967 · Cited by 19
“Individual biomarkers are detected in various stages of the AD continuum and are complementary to the clinical criteria in the diagnosis of AD dementia and its earlier stages [6,7].”
Backgroundβ-Amyloid peptide modulates peripheral immune responses and neuroinflammation in rats
Adhikary, K., Mohanty, S., Bandyopadhyay, B., Maiti, R., Bhattacharya, K., & Karak, P. (2024) · BioMolecular Concepts · doi:10.1515/bmc-2022-0042 · Cited by 18
“We performed the in fl ammatory cytokines markers (tumor necrosis factor-α (TNF-α ), interleukin-1 β , reactive oxygen species [ROS], and nitrite) in the hippocampus in A β -AD rats, placebo rats, and rats that underwent sham surgery (received phosphate-bu ff er saline or PBS) [18].”
MethodTargeting the molecular web of Alzheimer’s disease: unveiling pathways for effective pharmacotherapy
Jadhav, D., Saraswat, N., Vyawahare, N. S., & Shirode, D. S. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00775-8 · Cited by 19
“AD is more common in senior citizens [25].”
BackgroundZhao, Y., Zhang, J., Chen, Y., & Jiang, J. (2022) · Brain Sciences · doi:10.3390/brainsci12081067 · Cited by 16
Etiology, risk factors, treatments and current status of AlzheimerÓ?s disease in Mexico
Gomez‐Virgilio, L., Gutierrez, G. S. R., Silva‐Lucero, M., López-Toledo, G., & Cárdenas‐Aguayo, M. D. C. (2022) · Gaceta Médica de México · doi:10.24875/gmm.22000023 · Cited by 19
Alzheimer-Associated Neuronal Thread Protein: Research Course and Prospects for the Future
He, J., & Wang, R. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201273 · Cited by 17
“As findings regarding the pathophysiological, molecular, and structural changes in Alzheimer’s disease (AD) increased, some biomarkers have been developed as diagnostic tools; this has shifted the diagnosis of AD from qualitative symptoms to quan-tifiable dynamic biological alterations [1, 2].”
Systems biology of Alzheimer’s Disease: a scoping review of key pathways and mechanisms
Bice, P. J., Nho, K. T., Ertekin‐Taner, N., & Saykin, A. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00934-4 · Cited by 18
“changes [20].”
Hu, X., Liu, C., Wang, K., Zhao, L., Qiu, Y. L., Chen, H., Hu, J., & Xu, J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.842208 · Cited by 15
Ioannidou, S., Tsolaki, M., Ginoudis, A., Tamvakis, Α., Tsolaki, A., Makedou, K., & Lymperaki, E. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15050171 · Cited by 15
França, V. L. B., BEZERRA, E. M., da COSTA, R. F., Carvalho, H. F., Freire, V. N., & Matos, G. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00453 · Cited by 15
“23,24 These filaments undergo further aggregation and thickening.”
DeMarshall, C. A., Viviano, J., Emrani, S., Thayasivam, U., Godsey, G. A., Sarkar, A., Belinka, B. A., Libon, D. J., Nagele, R. G., & on behalf of the Parkinson’s Study Group and the Alzheimer’s Disease Neuroimaging Initiative (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221091 · Cited by 14
“…the fact that neurodegenerative changes associated with this disease can begin up to two decades before the onset of clinical symptoms, the task of identifying healthy and appropriately age-matched control subjects lacking early stages of AD pathology can be fraught with potential error [49, 50].”
Zhang, H., Liu, J., Zhang, N., Jeromin, A., & Lin, Z. J. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.155 · Cited by 12
Zhang, J., Ma, W., Liu, R., Li, X., Yuan, Z., & Cheng, J. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01648 · Cited by 15
Thakur, A., Rana, M., Vanjani, S., Liou, K.-C., Taliyan, R., Nepali, K., & Yang, C. (2026) · Medicinal Research Reviews · doi:10.1002/med.70047 · Cited by 12
Kushawaha, S. K., Ashawat, M. S., Soni, D., Kumar, P., Rimpi, & Baldi, A. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148906 · Cited by 12
Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Bacci, J. R., Karagianni, S., Alexopoulou, Z.-S., Moukaled, S., Tato-Fernández, C., Arunachalam, P., Aslanyan, A., Aye, S., Rocha, A. S. L., Crugel, M., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01921-5 · Cited by 12
“Aβ can be detected as Aβ40, the most common isoform of Aβ, and Aβ42, a fragment of the amyloid precursor protein [17].”
Niu, Y., Zhang, Y., Zha, Q., Shi, J., & Weng, Q. (2024) · Journal of Applied Genetics · doi:10.1007/s13353-024-00827-6 · Cited by 13
“Currently, it is believed that it is mainly related to gender, brain trauma, education level, reproductive age, viral infection, and other factors (Lloret et al. 2019).”
Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease
Safransky, M., Groh, J. R., Blennow, K., Zetterberg, H., Tripodis, Y., Martin, B. M., Weller, J. L., Asken, B. M., Rabinovici, G. D., Qiu, W. W. Q., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209866 · Cited by 10
Ferreira, D. A., Macedo, L. B. C., & Foss, M. P. (2023) · The Clinical Neuropsychologist · doi:10.1080/13854046.2023.2273574 · Cited by 10
“Dementia due to AD has a prolonged evolution that begins decades before its symptomatic manifestation, leading to cognitive decline and incapacity (Lloret et al., 2019).”
BackgroundThe Parietal Lobe in Alzheimer’s Disease and Blindness
Ahulló-Fuster, M.-A., Ortiz, T., Varela-Donoso, E., Nácher, J., & Sánchez-Sánchez, M. L. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220498 · Cited by 11
Identification of the molecular subgroups in Alzheimer's disease by transcriptomic data
Li, H., Wei, M., Ye, T., Liu, Y., Qi, D., & Cheng, X. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.901179 · Cited by 11
“The Nincds-Adrad core symptom scale, introduced in 1984, has been widely used in studies with an accuracy of 65– 96% but can only distinguish AD from other dementias with a specificity of 23–88% (2).”
MethodDiaz-Gomez, L., Gutierrez-Rodríguez, A. E., Martínez-Maldonado, A., Luna‐Muñoz, J., Cantoral-Ceballos, J. A., & Ontiveros‐Torres, M. Á. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44120406 · Cited by 10
“In summary, this evidence underlines the importance of the analysis by the occlusion algorithm for our further studies using early and late biomarkers in the pathological processing of Tau protein directed towards its amino-terminal and carboxyl-terminal end, respectively, which can be validated among different neurod…”
BackgroundResearch on Alzheimer's Disease (AD) Involving the Use of In vivo and In vitro Models and Mechanisms
Sinha, S., Wal, P., Prakash Goudanavar, S. O. P., Divya, S., Kimothi, V., Jyothi, D., Sharma, M. C., & Wal, A. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249293642240522054929 · Cited by 10
Lv, S., Zhou, X., Li, Y., Zhang, S., Wang, Y., Jia, S., Niu, X., Wang, L., & Peng, D. (2021) · Medical Science Monitor · doi:10.12659/msm.932998 · Cited by 9
Liu, H., Zhong, L., Dai, Q., Yang, J., Zhang, Y., Zhang, B., & Jiang, Y. (2021) · NeuroImmunoModulation · doi:10.1159/000516396 · Cited by 9
Wang, L., Yu, H., Hao, L., Ju, M., Feng, W., & Xiao, R. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200576 · Cited by 9
Association between BrainAGE and Alzheimer's disease biomarkers
Abughofah, Y., Deardorff, R. L., Vosmeier, A., Hottle, S., Dage, J. L., Dempsey, D. A., Apostolova, L. G., Brosch, J. R., Clark, D. G., Farlow, M. R., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70094 · Cited by 11
Early Diagnosis of Alzheimer's Disease using Convolutional Neural Network-based MRI
Kadhim, K. A., Mohamed, F., Sakran, A. A., Adnan, M. M., & Salman, G. A. (2023) · Malaysian Journal of Fundamental and Applied Sciences · doi:10.11113/mjfas.v19n3.2908 · Cited by 10
“Some of the early symptoms of Alzheimer's disease can be seen in imaging data contribute to delaying disease progression and help in obtaining necessary disease care. which must be used in combination with additional clinical knowledge outcomes to accurately classify the data [2].”
Potential Application of MicroRNAs and Some Other Molecular Biomarkers in Alzheimer’s Disease
Paprzycka, O., Wieczorek, J., Nowak, I., Madej, M., & Strzałka‐Mrozik, B. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46060304 · Cited by 7
“Currently, research is underway on methods to measure the levels of the two major forms of β -amyloid (A β 40 and A β 42) and phosphorylated tau protein in blood serum [17–19].”
MethodZheng, M., Su, W., Tian, L., & Gao, W. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150221 · Cited by 7
Novel mathematical model based on cellular automata for study of Alzheimer’s disease progress
Jafari, N., Sarbaz, Y., Kalan, A. E., & Golabi, F. (2022) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-022-00366-2 · Cited by 6
A Sandwich-Type Impedimetric Immunosensor for the Detection of Tau-441 Biomarker
Djebbi, K., Xiang, Y., Shi, B., Douadji, L., Chen, X., Liu, J., Tlili, C., & Wang, D. (2025) · Bioengineering · doi:10.3390/bioengineering12080805 · Cited by 5
“Different techniques have been established for AD monitoring, such as neuro-imaging methods [4,5]; however, these methods tend to be costly, require high-tech equipment, and often lack the required sensitivity and selectivity.”
Hybrid Deep Learning Algorithm For MRI Brain Alzheimer’s Disease Prediction
Karthikeyan, D., Nivasini, R., Raja, K. T., Madhivadhani, D., Sivakumar, B., & Priya, A. T. R. K. (2023) · International Conference on Energy, Materials and Communication Engineering (ICEMCE) · doi:10.1109/icemce57940.2023.10433984 · Cited by 9
“Early identification can help reduce the progression of AD and postpone the emergence of full-blown dementia as there is no effective treatment for avoiding this critical disease [11].”
BackgroundSociodemographic traits as early indicators of AD, FTD, and VaD up to 10 years before diagnosis
Kivisild, A., Rinnankoski, I., Aaltonen, M., Aho, K., Heikkinen, S., Lehtonen, A., Leppänen, L., Soppela, H., Tervonen, L., Ervasti, K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70616 · Cited by 4
“16,17 Different dementia phenotypes may also represent differing reasons for the higher unemployment rate in each time point before dementia diagnosis.”
ABBV‐552 in patients with mild Alzheimer's disease: a randomized phase IIb trial
Lynch, S. Y., Jia, J., Miles, N., Boiser, J. C., Buhl, D. L., Graff, O. X., & Zadikoff, C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70994 · Cited by 4
Bibliometric review on biomarkers for Alzheimer’s disease between 2000 and 2023
Yang, X., & Qu, H. (2023) · Medicine · doi:10.1097/md.0000000000034982 · Cited by 4
“[25] The existing biomarkers used for diagnosing AD include; 42 amino acid forms of amyloid β in the CSF; Total and phosphorylated tau proteins in CSF.[26] Aβ combined with p tau and t tau in the CSF has been established as an acceptable biomarker Table 4 Top 15 keywords in cited times.”
MethodBian, Z., Wang, B., Wu, X., Wang, K., & Jiang, Y. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s460421 · Cited by 4
Sidenkova, A. P., Litvinenko, V., Bazarnyi, V. V., Rezaykin, A. V., Zakharov, A. V., Baranskaya, L., & Babushkina, E. I. (2024) · Consortium Psychiatricum · doi:10.17816/cp15526 · Cited by 4
Recent Advancements in the Early Diagnosis and Treatment of Alzheimer's Disease
Wu, Y., Fu, L., Li, Q., Gao, X., Zhang, Y., Jin, C., Ding, F., Hong, S. C., Cai, H., & Li, Y. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300181 · Cited by 5
Characterizing olfaction, anxiety, and depression in subjective cognitive decline
Fortier-Lebel, O., Hudon, É., Brosse, S., Boller, B., & Frasnelli, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251363422 · Cited by 4
“9 The accumulation of tau neuro fi brillary tangles fi rst impacts the transentorhinal cortex and entorhinal cortex, spreading to the limbic system, including the hippocampus and eventually reaching the entire cortex.”
Coppola, V. J., Scribner, H. R., Barnett, C., Flanigan, K. A. S., Riesgo, V. R., & Bingman, V. P. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137754 · Cited by 2
Gouveia, A. S. A., Oliveira, L. R., Matias, D. A., & Silva, W. S. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n3-312 · Cited by 2
Liquid clues: tear film biomarkers unravelling Alzheimer’s mysteries
Zaheer, A., Anwar, I. B., Haseeb, A., & Yadav, A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002014 · Cited by 2
“PiB-PET utilizes Pittsburgh com-pound-B as a ligand for A β to examine the distribution and quantity of cerebral A β [8] .”
MethodGiudici, K. V. (2024) · Journal of Aging Research and Lifestyle · doi:10.14283/jarlife.2024.10 · Cited by 2
“It is known that AD slowly develops for decades before cognitive decline is perceptible and starts negatively affecting a person’s life (2).”
BackgroundMethodLeong, V., Yu, J., Castor, K., Al‐Ezzi, A. A. A., Arakaki, X., & Fonteh, A. N. (2024) · Cells · doi:10.3390/cells13110970 · Cited by 2
“At the same time, insufficient concentrations correspond to mental exhaustion [12,13]. the same time, insu ffi cient concentrations correspond to mental exhaustion [12,13].”
BackgroundNew Research on Biomarkers in Alzheimer’s Continuum
Vecchio, I., & Colica, C. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871331138250114052615 · Cited by 3
Mazel, P., Foray, N., & Pujo-Menjouet, L. (2025) · Lecture notes on mathematical modelling in the life sciences · doi:10.1007/978-3-031-82396-1_5 · Cited by 2
Wei, X., Liu, X., Ban, Y., Li, J., & Rong, H. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11169-1 · Cited by 1
Kumar, P., Chandel, S. S., Yadav, N., Vaishnaw, A., & Rai, M. (2025) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2025.00039 · Cited by 1
Faeed, M., Hosseini, H., Abdollahi, A., Aziz, M., Darabi, H., Sohrabi-Ashlaghi, A., Farhadi, S., Nobari, M. N., & Badakhshan, H. (2026) · BMC Neurology · doi:10.1186/s12883-026-04758-z · Cited by 1
“…tangles inside the neurons is widely regarded as the central pathological mechanism underlying the deterioration of neuronal function, ultimately resulting in cognitive impairment, dementia, and neuropsychiatric symptoms including aggression/ agitation, mood change and hallucination [2, 3].”
Ferroptotic neurodegeneration and diet: a narrative review
van der Burg, X. R., Toen, D. V., Ayton, S., Pijl, H., & van der Weerd, L. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71368 · Cited by 1
“4 The association between diet and neurological function has been extensively reported.”
Choi, J. J., Engelman, C. D., & Lu, T. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261487621 · Cited by 1
“8 In recent years, transcriptomics and metabolomics have emerged as key omics approaches for investigating the molecular basis of AD.”
Relationships Between Treatment and Clinical Evaluations
Pardi, P. C., & dos Santos, G. A. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-94383-7_9 · Cited by 1
Updates in Geriatric Psychiatry
(2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19301 · Cited by 1
Munchausen Syndrome and post-traumatic stress disorder- a correlation
Ciobanu, R.-P., Moraru, C., Rădulescu, I.-D., Albu, E., Nechita, P., & Rusu-Zota, G. (2022) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2022.2.13 · Cited by 1
Alzheimers disease: A dental approach
Guerrero, K. G. V., Meester, I., Gonzalez, S. D. C. R., González, Y. M., Cepeda, S. E. N., Delgadillo, R. H., Romero, C. C., Arenas, I. A. V., & Soto, J. M. S. (2023) · International Journal of Applied Dental Sciences · doi:10.22271/oral.2023.v9.i1a.1656 · Cited by 1
Alzheimer e doença periodontal
Cambon, P. T. (2020) · Repositório Comum (Repositório Científico de Acesso Aberto de Portugal) · Cited by 1
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6 · Cited by 1
Bjorkli, C., Hemler, M. E., Julian, J. B., Sandvig, A., & Sandvig, I. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.14.476357
The cognitive performance in the Phototest is predictor of biological markers of Alzheimer's disease
Carrera-Muñoz, I., Barrios-López, J. M., Claudia, M., Romero‐Fábrega Juan, C., Vilchez‐Carrillo Rosa, M., Teodoro, D. S. Q., & Cristoba, C. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5792
Metadata
- Authors
- Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P.
- Affiliations
- Universitat de València (ES)
- Department of Clinic Neurophysiology. University Clinic Hospital of Valencia, Avda. Blasco Ibanez, 19, 46010 Valencia, Spain
- Department of Human Anatomy and Embriology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain
- Hospital Clínico Universitario de Valencia (ES)
- Corresponding author
- Lloret, Ana
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-11-06
- Volume
- 20
- Issue
- 22
- Pages
- 5536
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6888399
- OpenAlex
- W2985526400
- Cited by
- 131
- References
- 117
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 22 · 2021: 19 · 2020: 2
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Ministerio de Economía, Industria y Competitividad, Gobierno de España (SAF2016-75508-R)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, disease onset, biomarkers, preclinical Alzheimer's disease, mild cognitive impairment, dementia, amyloid-beta, tau protein, glucose hypometabolism, brain atrophy, NIA-AA criteria, disease continuum, early diagnosis
- MeSH terms
- Alzheimer Disease, Humans, Risk Factors, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.